TRANXENOGEN, INC. TranXenoGen Research/Evaluation Agreement with Amgen for Monoclonal Antibody Production September 7, 2001 - TranXenoGen, Inc. ("TranXenoGen" or the "company"), the US based biotechnology company listed on AIM (TXN.L) which is establishing itself as a leading protein drug manufacturing company using its proprietary avian transgenic technology, announces an agreement with Amgen Inc., the world’s largest independent biotechnology company, to evaluate TranXenoGen’s avian transgenic technology for monoclonal antibody production. The agreement with Amgen to develop transgenic chickens expressing Amgen’s monoclonal antibody is the latest agreement signed by TranXenoGen. Under the agreement, Amgen will provide the antibody gene (to be determined) to TranXenoGen and TranXenoGen will provide its expertise to conduct a feasibility study designed to evaluate transgenic chickens as a potential production methodology. TranXenoGen’s current strategy is to demonstrate the value of its avian transgenic technology for the high-volume, low-cost manufacture of monoclonal antibody products and other therapeutic proteins by entering into development agreements with industry leaders in this field. Consequently evaluation programs were launched at the end of last year with KS Biomedix and a major US biotechnology company involved in antibody development. More recently in March, an agreement was announced with Abbott Laboratories to demonstrate production of a proprietary antibody, and this agreement with Amgen extends the list of high quality relationships. Transgenic technologies, such as TranXenoGen’s, avoids the need for huge capital investment in conventional mammalian cell culture facilities and has the potential to deliver product at a fraction of the cost with the ability to rapidly scale-up production. For these reasons, TranXenoGen has targeted the growing monoclonal antibody market as the ideal product area to exploit its avian transgenic technology. Kim Tan, Chairman, TranXenoGen commented: "This is an important agreement for TranXenoGen. We are pleased to be working with Amgen, a worldwide leader in the development and production of therapeutic proteins. "We continue to believe that the most important application of our technology is to the area of high-volume therapeutic proteins that are difficult and costly to develop using conventional technologies. TranXenoGen’s technology will enable life saving products to reach the market that might not otherwise make it, by offering low-cost scaleable production. "The Company now has four world-class companies with whom it is working to develop monoclonal antibodies." Enquiries: TranXenoGen, Inc Tel: 001 508 842 5036 Kim Tan, Chairman College Hill Associates Tel: 020 7457 2020 Michael Padley/Nicholas Nelson Email: nicholas.nelson@collegehill.com Notes to Editors TranXenoGen, Inc. (symbol: TXN.L) is a publicly listed company on the Alternative Investment Market of the London Stock Exchange. The company specializes in the application of second-generation transgenic technology to the production of complex high-volume human therapeutic proteins in the egg albumin fraction of transgenic chicken eggs.